ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-20

Key Insights

Arrowhead Pharmaceuticals held its 2026 Annual Meeting, where key proposals were approved by shareholders, including the election of directors and the adoption of an amended incentive plan.
The 'Say-on-Pay' proposal for executive compensation was rejected by shareholders, indicating potential concerns over the company's executive pay practices.
The company maintained its independent auditor, KPMG LLP, for the 2026 fiscal year, suggesting continuity in financial reporting and oversight.

Want the newest filings?

This analysis covers the filing from 2026-03-20. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-05

Arrowhead Pharmaceuticals reported its fiscal 2026 financial results, with details on its operations and performance over the period ended December 31, 2025.
The company did not provide any information on new material agreements, leadership changes, or earnings surprises in this 8-K filing.
As this appears to be a routine quarterly earnings report, the significance and potential impact on the stock is relatively low.

Filed: 2026-01-12

Arrowhead Pharmaceuticals issued $700 million in convertible senior notes due in 2032, which can be converted into the company's common stock at an initial price of $87.07 per share.
The notes do not bear regular interest, but special interest may accrue up to 0.50% per annum if the company fails to file certain SEC reports.
The notes are redeemable at the company's option starting in January 2029, but only if the stock price exceeds 130% of the conversion price for a specified period.

Filed: 2026-01-09

Arrowhead Pharmaceuticals raised $216.6 million through a public offering of common stock and pre-funded warrants, which will provide additional capital to fund their operations and development programs.
The company also raised $681.3 million through the issuance of $700 million in convertible senior notes due 2032, which will further strengthen their balance sheet and financial flexibility.
The timing of these capital raises suggests that Arrowhead Pharmaceuticals may have significant growth opportunities and potential upcoming milestones that require additional funding.

Filed: 2026-01-06

Arrowhead Pharmaceuticals reported positive interim results from Phase 1/2a clinical trials of two of its investigational RNA interference (RNAi) therapeutics, ARO-INHBE and ARO-ALK7, for the treatment of obesity.
ARO-INHBE demonstrated dose-dependent reductions in serum Activin E, as well as improvements in body composition including visceral fat reduction, liver fat reduction, and increased lean tissue.
ARO-ALK7 showed the first RNAi-therapeutic to demonstrate adipocyte gene target silencing in a clinical trial, with rapid dose-dependent reductions in mean visceral fat.

Other reports for ARROWHEAD PHARMACEUTICALS, INC.

Insider Trading Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.